Can a peer coach help you beat opioid addiction? small trial aims to find out
NCT ID NCT07620171
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding peer recovery support—coaching from someone who has personally overcome opioid addiction—to standard medication treatment (buprenorphine) helps people stay in care longer. Fifteen adults with opioid use disorder will receive peer support for 180 days alongside their usual treatment. Researchers will track how long participants remain in treatment and whether they report less opioid use.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Peer recovery support services (behavioral intervention)
- What this could lead to
- If it works, this could point toward a practical way to help people with opioid use disorder stay in treatment longer and reduce relapse.
- What could go wrong
- This is a very small pilot study with only 15 participants, so results may not apply widely. The intervention may not improve retention or may be hard to deliver consistently.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 15 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2026
- Expected to finish
-
Oct 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18 years or older * Diagnosis of opioid use disorder (OUD) * Currently receiving or initiating buprenorphine treatment from a primary care physician * Able to communicate in English * Access to a phone * Able and willing to provide written informed consent Exclusion Criteria: * Acute suicidal ideation or intent * Active mania or psychotic episode * Significant cognitive impairment
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Buprenorphine are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Penn Family Medicine
Philadelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can exercise boost brain and body health during opioid treatment?
- Can a new drug calm the storm of opioid withdrawal?
- Can coaching turn rural clinics into One-Stop shops for addiction and infectious disease care?
- Can a Phone-Based platform keep people in opioid treatment?
- A safety net after jail: can checkups keep opioid treatment on track?
- Can AI and peer support close the opioid treatment gap?